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Abstract: Chronic intestinal inflammation is characteristic of Inflammatory Bowel Disease (IBD) that
is associated with the exaggerated infiltration of immune cells. A complex interplay of inflammatory
mediators and different cell types in the colon are responsible for the maintenance of tissue homeostasis
and affect pathological conditions. Gene expression alteration of colon biopsies from IBD patients
and an in vivo rat model of colitis were examined by RNA-Seq and QPCR, while we used in silico
methods, such as Ingenuity Pathway Analysis (IPA) application and the Immune Gene Signature
(ImSig) package of R, to interpret whole transcriptome data and estimate immune cell composition of
colon tissues. Transcriptome profiling of in vivo colitis model revealed the most significant activation
of signaling pathways responsible for leukocyte recruitment and diapedesis. We observed significant
alteration of genes related to glycosylation or sensing of danger signals and pro- and anti-inflammatory
cytokines and chemokines, as well as adhesion molecules. We observed the elevated expression
of genes that implies the accumulation of monocytes, macrophages, neutrophils and B cells in the
inflamed colon tissue. In contrast, the rate of T-cells slightly decreased in the inflamed regions.
Interestingly, natural killer and plasma cells do not show enrichment upon colon inflammation. In
general, whole transcriptome analysis of the in vivo experimental model of colitis with subsequent
bioinformatics analysis provided a better understanding of the dynamic changes in the colon tissue
of IBD patients.
Keywords: inflammatory bowel disease (IBD); immune cell gene signature (ImSig); whole
transcriptome analysis
1. Introduction
Inflammatory bowel disease (IBD) is an umbrella term of chronic inflammatory disorders of the
gastrointestinal tract [1]. Its main types are Crohn’s disease (CD) and ulcerative colitis (UC), whose
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incidence is increasing worldwide but mostly concern westernized countries [2]. Symptoms of CD
and UC influence the everyday life of patients, because disruption of intestinal homeostasis not only
eventuate bloody diarrhea, bloating, abdominal pain and cramps, malabsorption and fatigue, but also
narrow down social life and trigger depression [1,3]. As a remittent disorder, it is characterized by the
fluctuation of nearly asymptomatic remission and symptomatic recurrence phases, when sporadically
located inflamed lesions appear along the intestine [1].
The molecular background of IBD is extremely complex because of its multifactorial
pathogenesis [4]. Previous studies described the effects of genetic alterations, environmental factors,
life-style habits and the microbiome in the progression of IBD, but their independent examination may
lead astray [4,5]. Whole genome association studies have established the importance of mutations
affecting genes with diverse roles in the communication between host and microbiome, such as NOD2
or FUT2 [6–8]. Characterization of gut flora of healthy individuals and IBD patients is currently a
popular field of research, but it has not been ascertained yet whether the alteration of microbiome is
the cause or the consequence of the disease [9,10]. Heterogeneity in the manifestation of symptoms,
genetic background or the microbiome between individual patients obstruct the efficient determination
of a general master regulator in this multilevel system.
Accordingly, instead of focusing only on certain molecules or mutations, the comprehensive
investigation of gene expression patterns is more informative in defining the consequences of the
interactions between these various factors. Whole transcriptome analysis of an in vivo model
of experimentally induced colitis represents a snapshot of the inflamed colon, and enables the
simultaneous observation of thousands of mRNA molecules. In this work we examined different
aspects and participants of inflammatory response by following an axis from the gut lumen through
the network of tissue resident and infiltrating immune cells to the endothelial cells of the vascular
wall, by the measurement of gene expression pattern of affected genes in rat and human colon tissue
samples. Furthermore, we applied several bioinformatics tools in order to decipher more precisely the
detected gene expression signatures. We determined the activated signaling pathways by applying
Ingenuity Pathway Analysis (IPA); in addition, we used the ImSig package of R to define the immune
cell composition of colon tissues based on gene expression signatures.
2. Materials and Methods
2.1. In Vivo Rat Model and Sample Collection
To investigate the molecular background of IBD we used the 2,4,6-trinitrobenzene sulfonic acid
(TNBS) induced rat model of experimental colitis. Male Wistar rats (180–220 g) were randomly divided
into two groups as detailed in [11]: the first group served as control, and the second group was induced
by TNBS (colitis-induced) based on the method described by Morris et al. [12]. Seventy-two hours after
the treatment, all animals were sacrificed and distal colons were removed. In the control group (n = 2),
samples were taken from random colon sections, while samples from colitis-induced animals were
taken from the inflamed colon region (n = 6) as well as from a non-adjacent uninflamed region (n = 6).
All samples were kept in TRIzol reagent (Thermo Fisher Scientific, Waltham, United States) at −80 ◦C.
2.2. IBD Patients
Colonic biopsies were obtained from 21 consenting patients with IBD (Table 1, 13 females and
eight males; median age 41 years, 25–74 years) undergoing colonoscopy for diagnostic purposes
approved by Hungarian Medical Research Council (ETT, Budapest, Hungary) Medical Research
Council’s Committee of Scientific and Research Ethics (TUKEB) as described previously [13]. Human
colonic biopsies were obtained by experienced gastroenterologists at the 1st Department of Internal
Medicine, University of Pécs in accordance with the guidelines set out by the Medical Research
Council of Hungary. Sample collection and classification was performed according to disease status of
patients, active/relapsing or inactive/remission phase. Furthermore, samples from relapsing patients
Biomolecules 2020, 10, 974 3 of 21
were subdivided as uninflamed or inflamed according to the status of colon tissue. To classify
uninflamed from inflamed samples, macroscopic diagnostic features were used in accordance with
the recommendations of the European Crohn’s and Colitis Organisation [14]. Multiple samples were
obtained both from visible lesions and from mucosa which is normal on gross inspection. Classically,
the mucosa in UC has a friable granular appearance and shows superficial ulcers. The earliest visible
mucosal lesions of CD are small aphthous ulcers, after which they coalesce to large deep serpiginous
or linear ulcers.
Table 1. Demographic data for study participants. Patient records were reviewed for disease
state (inactive, active), tissue state (inflamed, uninflamed), Inflammatory Bowel Disease (IBD) type
(Crohn’s Disease, CD; Ulcerative Colitis, UC; IBD indeterminate, UC/CD), biopsy location (colon
ascendens/transversum/descendens/sigmoideum), age (year, y), sex (male, M; female, F) and disease
duration (year, y).
Disease
State IBD
Patient
ID
Sample
ID Sex
Age,
y Biopsy Location
Tissue
State
Disease
Duration, y
inactive CD 1 H1 M 47 colon descendens − 27
inactive CD 2 H3 M 32 colon ascendens − 7
inactive UC 3 H5 F 36 colon ascendens − 16
inactive CD 9 H27 F 39 colon ascendens − 17
inactive CD 9 H28 F 39 colon descendens − 17
inactive UC 16 H50 F 72 colon ascendens − 12
inactive UC 16 H51 F 72 colon descendens − 12
inactive UC 33 H99 M 56 colon ascendens − 21
inactive UC 33 H100 M 56 colon transversum − 21
inactive UC 33 H101 M 56 colon descendens − 21
active UC/CD 4 H10 F 41 colon ascendens uninflamed 20
active UC/CD 4 H12 F 41 colon transversum uninflamed 20
active UC 6 H18 F 27 colon ascendens uninflamed 2
active UC 6 H21 F 27 colon descendens uninflamed 2
active CD 10 H31 F 43 colon transversum uninflamed 9
active UC 11 H32 F 44 colon ascendens uninflamed 11
active CD 12 H35 M 37 colon ascendens uninflamed 3
active CD 15 H48 F 37 colon ascendens uninflamed 12
active CD 15 H49 F 37 colon descendens uninflamed 12
active UC 17 H56 M 51 colon descendens uninflamed 14
active UC 18 H58 F 47 colon sigmoideum uninflamed 17
active UC 20 H62 F 41 colon sigmoideum uninflamed 12
active CD 22 H68 F 24 colon transversum uninflamed 6
active UC 28 H86 M 49 colon descendens uninflamed 20
active CD 29 H88 M 33 colon ascendens uninflamed 11
active UC/CD 4 H9 F 41 colon ascendens inflamed 20
active UC/CD 4 H11 F 41 colon transversum inflamed 20
active UC 6 H19 F 27 colon ascendens inflamed 2
active UC 6 H20 F 27 colon descendens inflamed 2
Biomolecules 2020, 10, 974 4 of 21
Table 1. Cont.
Disease
State IBD
Patient
ID
Sample
ID Sex
Age,
y Biopsy Location
Tissue
State
Disease
Duration, y
active CD 8 H25 M 30 colon transversum inflamed 14
active CD 12 H36 M 37 colon descendens inflamed 3
active UC 13 H39 F 33 colon descendens inflamed 11
active UC 17 H54 M 51 colon ascendens inflamed 14
active UC 17 H55 M 51 colon transversum inflamed 14
active UC 18 H57 F 47 colon sigmoideum inflamed 17
active UC 20 H63 F 41 colon sigmoideum inflamed 12
active CD 22 H69 F 24 colon sigmoideum inflamed 6
active UC 24 H74 M 42 colon transversum inflamed 21
active UC 24 H75 M 42 colon sigmoideum inflamed 21
active UC 28 H87 M 49 colon sigmoideum inflamed 20
active CD 29 H89 M 33 colon sigmoideum inflamed 11
2.3. Extraction of Total RNA
Samples from rat colons were homogenized in TRIzol reagent by ULTRA-TURRAX T-18 (IKA)
instrument as described previously [15]. In total, 0.1 mL of chloroform (Sigma-Aldrich, Haverhill,
United Kingdom) was added to 0.3 mL homogenized sample with vigorous vortexing. Samples
were centrifuged at 13,000 rpm for 10 min. Total RNA was than extracted from the upper aqueous
phase. RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) was used to purify total RNA from rat colon
samples according to the manufacturer’s protocol. Total RNA from human biopsies was isolated using
NucleoSpin RNA Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s protocol.
The quality and the quantity of the extracted RNAs were determined by TapeStation (Agilent, Santa
Clara, United States) and Qubit Fluorometer (Thermo Fisher Scientific).
2.4. Reverse Transcription and Quantitative Real-Time PCR (QPCR)
Reverse transcription was performed by SuperScript VILO Master Mix (Thermo Fisher Scientific)
according to the manufacturer’s instructions. Gene expression was measured by quantitative real-time
PCR using the StepOne PCR Systems (Thermo Fisher Scientific). SybrGreen technology based QPCR
reactions were performed by SYBR Select Master Mix (Thermo Fisher Scientific) with specific exon
spanning primer sets (Tables 2 and 3), while TaqMan technology based reactions were performed by
TaqMan Fast Advanced Master Mix and TaqMan Gene Expression Assays (Table 4) (Thermo Fisher
Scientific). The ratio of each gene relative to the 18S rRNA was calculated using the 2−∆∆CT method.
Table 2. SybrGreen primer sets used in QPCR experiments for rat samples.
Gene ID Forward (5′-3′) Reverse (5′-3′)
Cxcl1 CATTAATATTTAACGATGTGGATGCGTTTCA GCCTACCATCTTTAAACTGCACAAT
Fut1 AGGACCCGTTTCTCAAGCTG CTATCCGGAGCCCACTCAAC
Fut2 ACTTCCACCATCATCCACCTC CTCTGGGCTTTCTGTGTTTCC
Fut4 AAGCTACAGCATGAGAGCCG AGAGGAGGTCCGGGGTAATC
Fut9 CAACAAATCCCATGCGGTCC CAATGCCACTCTTTTGGGGG
Il1β CAGGAAGGCAGTGTCACTCA AGACAGCACGAGGCATTTTT
Il6 CACTTCACAAGTCGGAGGCT TCTGACAGTGCATCATCGCT
Nlrc4 GCGAAACCTGAAGAAGATGC AACGCTCAGCTTGACCAAAT
Nlrp3 GCTGCTCAGCTCTGACCTCT AGGTGAGGCTGCAGTTGTCT
Nlrp6 TACCTGGTCATTGTGCTCCA TCAGAGGCTGAGGATGTGTG
Nod2 TCCTTGCACACAAGCAGAAC TGATCAGCCACAACTTCAGC
Tnf ATGGGCTCCCTCTCATCAGT GCTTGGTGGTTTGCTACGAC
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Table 3. SybrGreen primer sets used in QPCR experiments for human samples.
Gene ID Forward (5′-3′) Reverse (5′-3′)
CCL2 CCTTCATTCCCCAAGGGCTC CTTCTTTGGGACACTTGCTGC
CDH5 GAGAATGACAATGCCCCGGA ACTGTGATGTTGGCCGTGTT
CXCR4 GGTGGTCTATGTTGGCGTCT ACACAACCACCCACAAGTCA
FN1 GGGCGAGGGAGAATAAGCTG TCTCAGCTATGGGCTTGCAG
FUT1 TGGCCGGTTTGGTAATCAGA TCCGACATCCAGTCGTGAAG
FUT2 TGGACCTTCTACCACCACCT CCACCCCCTTCCACACTTTT
FUT4 GCCTCGTACCTGCTTTTCCT AGTTCCGTATGCTCTTGGGC
FUT9 CCATACCTACGGGCAAGCAT ACAACAGGTACAGAGCCAGC
ICAM1 TGACCGTGAATGTGCTCTCC TCCCTTTTTGGGCCTGTTGT
ICAM2 TCTGCTGTCCAGGATCGGA TTTCCACTGAGCCTGTTCGT
IL1β AGCTGGAGAGTGTAGATCCCAA GGGAACTGGGCAGACTCAAA
ITGA4 CGCTTCAGTGATCAATCCCG CTCCATTAGGGCTACCCAGC
ITGA5 TGGCCTTCGGTTTACAGTCC GGAGAGCCGAAAGGAAACCA
ITGB2 TGGATGAGAGCCGAGAGTGT CAGCAGGAGAATGCCGATCA
ITGB7 TCGCAGCACAGAGTTTGACT CTGTACCACGTTGCTGGAGT
MMP12 CGGGCAACTGGACACATCTA CCTCACGGTTCATGTCAGGT
MMP14 GGCGGGTGAGGAATAACCAA ACGCCTCATCAAACACCCAA
MMP2 GCCCTGATGGCACCCATTTA GTCAGGAGAGGCCCCATAGA
MSN TCTGCAAGTGAAAGAGGGCA CCTCCCACTGGTCCTTGTTG
NLRC4 GGACAATAGCCGAGCCCTTA CCACCTTCTCGCAGCAAATG
NLRP3 AAGGCCGACACCTTGATATG CCGAATGTTACAGCCAGGAT
NLRP6 CAGTTCTCAAGGCACCACAA TCACTCAGCATACGCAGTCC
NOD2 CTCCATGGCTAAGCTCCTTG CACACTGCCAATGTTGTTCC
SELE GCCTGCAATGTGGTTGAGTG GGTACACTGAAGGCTCTGGG
SELL GCCTGCCACAAACTAAAGGC TCACAAACTGACACTGGGGC
SELP CCAACCTGCAAAGGCATAGC GTGTGAATCCAGCGTTGCAG
SELPLG AGAAGGAGATAAGATGGCTGGTG ACTCATATTCGGTGGCCTGTC
Table 4. TaqMan Gene Expression Assays.
Gene ID Assay Number
IL1α Hs00174092_m1
IL6 Hs00174131_m1
IL8 (CXCL8) Hs00174103_m1
IL10 Hs99999035_m1
TNFAIP3 Hs00234713_m1
TNFAIP6 Hs01113602_m1
TNF Hs00174128_m1
18S RNA Hs99999901_s1
2.5. Whole Transcriptome Analysis by RNA-Seq and Bioinformatics
RNA-Seq was performed by SOLiD total RNA-Seq Kit (Thermo Fisher Scientific), according to the
manufacturer’s instructions, and sequenced on SOLiD 5500xl instrument using the 50-base sequencing
chemistry. Raw sequence data was size-selected discarding reads shorter than 50 bp. Rnor_5.0
(GCA_000001895.3) from ENSEMBLE release 77 was used as a reference to align RNA-Seq data. Legacy
RNA-Seq engine of CLC Genomic Workbench tool (Qiagen, v7.5.1) was used to obtain gene expression
estimates (mapped read counts) for each annotated gene in all samples with the following mapping
parameters: maximum number of mismatches: 2, minimum alignment length fraction: 0.8, minimum
similarity fraction: 0.8, unspecific match limit: 10. Reads mapping to rRNA genes were removed.
Subsequently, “calcNormFactors” from package “edgeR” was used to perform data normalization
based on the “trimmed mean of M-values” (TMM) method. Common and tagwise negative binomial
dispersion values were estimated in edgeR using “estimateCommonDisp” and “estimateTagwiseDisp”
functions of edgeR package, respectively. Lists of differentially expressed genes were obtained via
the “exactTest” function of edgeR. After data normalization, genes showing at least two-fold gene
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expression change with a false discovery rate (FDR) value below 0.05 were considered significant.
Multi-dimensional scaling was also applied to visually summarize gene expression profiles, revealing
similarities between samples and unsupervised cluster analysis was carried out on the normalized
data. Function plotMDS() from package Limma was used to generate Figure 1A. This tool performs
multidimension scaling on the sample-sample distance data calculated from gene expression profiles.
Distance between each pair of samples is determined as the root-mean-square deviation (Euclidean
distance) for the top N genes (N = 500 in our analysis) that display the highest fold change between the
given two samples. Such distance values can be interpreted as “leading log2-fold-change,” meaning
the typical log2-fold-change of the top N genes that distinguish the compared two samples. Values in
the x and y axis of the multidimensional scaling (MDS) plot also represent this distance calculation
logic. The first two dimensions of the MDS scaling were calculated to account for 37.7% and 10.5% of
the variance in data, respectively.
2.6. Pathway Analysis
For the interpretation of transcriptomic data and for the definition of functional relationship
between significantly changed molecules, we used the Ingenuity Pathway Analysis (IPA) application
(http://www.ingenuity.com). Database of IPA (Knowledge Base) is based on published experimental
results. Significantly activated canonical pathways in the in vivo model of experimental colitis were
determined by core analysis function of IPA by using log fold change and FDR values. Determination of
significantly activated canonical pathways was based on two different methods. The most significantly
altered canonical pathways between sample groups of RNA-Seq analysis were calculated using a
Right-Tailed Fisher’s Exact Test; it reflects the likelihood that the association or overlap between a set
of significant molecules from the experiment and given process/pathway transcription neighborhood
is due to random chance. The smaller the p-value, the less likely that the association is random; for a
clear visualization, values were transformed into negative log scale, where a higher “–log(p-value)”
means it is less likely that the association is random. By using the downstream effect activation of the
z-score, a statistical measure of the correlation between the relationship direction and the resulting
gene expression were performed. Z-score > 2 or < −2 is considered significant, which can be applied in
some analysis types, and provides predictions about upstream or downstream processes. It takes into
account the directional effect of one molecule on another molecule or on a process, and the direction of
change of molecules in the dataset.
2.7. Translation of Homologous Immune Signature Gene IDs
We used the Complete List of Vertebrate Homology Classes database of the Mouse Genome
Database (MGD) [16] to identify the homologous Rattus norvegicus gene IDs of the Homo sapiens Immune
Signature genes. Out of the 569 immune human signature genes, we found 476 IDs in the MGD
database, and an additional 41 homolog/ortholog IDs were identified manually using the resources of
NCBI and HGNC databases, while we did not find a rat counterpart of 52 human signature genes.
2.8. Immune Signature Analysis
According to the recommendations of the original manuscript [17], we used the prenormalized
(calculated expression signal of a gene per sample) transcriptomic data from SOLiD 5500xl platform
for this analysis. Normalization of gene expression data was performed by the TMM method of edgeR
package (version 3.24.3) and a conservative correlation threshold (r = 0.7) was used for feature selection
and immune signature analysis (ImSig R package, version 1.0.0).
2.9. Statistical Analysis, Data Representation and Data Availability
Statistical evaluations were performed using the IBM SPSS Statistics program for Windows.
Graphs were plotted with GraphPad Prism 6 software or by ggplot package of R. Quantitative data are
presented as the mean ± SEM and the significance of difference between sets of data was determined
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by one-way analysis of variance (ANOVA) following LSD post-hoc test; a p value of less than 0.05 was
considered significant.
Gene Expression Omnibus (GEO) archive of the three sequenced libraries was deposited in NCBI’s
GEO Archive at http://www.ncbi.nlm.nih.gov/geo under accession GSE149517.
3. Results and Discussion
3.1. Global Gene Expression Pattern of In Vivo Model of Colitis
In the widely used 2,4,6-trinitrobenzene sulfonic acid (TNBS) induced rat model of IBD the
intracolonically-administered TNBS destroys the integrity of intestinal epithelium and generates
sporadically located lesions [18]. Hence, inflamed, phenotypically normal and uninflamed tissue
regions alternate along the colons, similar to that observed in the digestive tract of IBD patients [1]. To
investigate the transcriptional changes after TNBS induction in different regions of the colon, we took
samples from both the inflamed and the uninflamed tissue areas and compared them to untreated
control samples using whole transcriptome analysis by RNA-Seq. After the standard processing of raw
sequencing data by bioinformatics tools, as described in Section 2.5, multidimensional scaling (MDS)
was performed to visually summarize gene expression profiles revealing similarities and differences
between samples. In silico performed MDS of individual transcriptomic data demonstrated clustering
of samples into control, TNBS treated uninflamed and TNBS treated inflamed groups (Figure 1A). In
addition, heat map representation of significantly altered transcripts confirmed differences between
inflamed and uninflamed samples of TNBS treated animals, whereas control and uninflamed samples
proved to be very similar at global transcriptomic level (Figure 1B).
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Figure 1. In silico performed multidimensional scaling (MDS) of individual transcriptomic data
clustered samples into control, 2,4,6-trinitrobenzene sulfonic acid (TNBS)-treated uninflamed and
TNBS-treated inflamed groups, while examination of significantly altered transcripts confirmed these
observations. (A) MDS of individual rat colon samples and (B) Representative heatmap image
of significantly altered transcripts in the control (green, n = 2), TNBS-treated uninflamed (yellow,
n = 6), TNBS-treated inflamed (red, n = 6) tissues. The heatmap contains 3766 genes that displayed
significant gene expression change in at least one of the three comparisons made. In the sample IDs, the
abbreviations “C,” “UI” and “I” represent control, uninflamed and inflamed sample groups, respectively.
Based on two independent methods, TNBS treated uninflamed and inflamed regions of the colon
significantly differ from each other at transcriptional level. To quantify the transcriptomic data, we
compared gene expression values of sample groups to each other. The expression of ~3800 transcripts
changed significantly in at least one of the three different ways of comparisons, namely TNBS treated
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–uninflamed vs. control (abbreviated as UI-C), TNBS-treated–inflamed vs. control (abbreviated as I-C)
and TNBS treated-inflamed vs. TNBS treated–uninflamed (abbreviated as I-UI).
3.2. Correlation between Murine and Human Samples
To validate our transcriptome data, first we compared the RNA-Seq results to our previous data on
gene expression changes related to epithelial-to-mesenchymal transition (EMT) [13,15,19]. Upon EMT,
epithelial cells lose their epithelial characteristics, their cell-cell connections disintegrate and cell motility
enhances. This process is associated with the formation of intestinal fibrosis and may play a role in the
development of IBD-related colorectal cancer [20]. We have previously reported that the expression
of EMT activating genes significantly increased both in the inflamed colon samples of TNBS treated
rats as well as in IBD patients [13,15,19]. In addition, the expression of growth factors (EGR1, FGF2
and FGF7), signal transducer molecules (JAK2, NOTCH2 and HIF1α), EMT inducing transcriptional
factors (ZEB2, SNAI1), extracellular matrix remodeler MMP9 and mesenchymal markers (LOX and
VIM) are all upregulated in the inflamed colon tissues, while the expression of the epithelial marker
CDH1 decreased [13,15,19]. Here, we report perfect overall correlation between the aforementioned
QPCR measurements and our current RNA-Seq results for all 12 genes (Supplementary Figure S1),
indicating that the RNA-Seq data are of high quality, thus allowing further analysis.
3.3. In Silico Analysis of Transcriptomic Data
In order to better understand results obtained by RNA-Seq and to identify possible relationship/s
between molecules with altered expression, next, we performed in silico pathway analysis by using
IPA. Functional analysis of our data sets revealed significant alteration of canonical pathways related to
communication between immune cells, immune cell recruitment, signaling through pattern recognition
receptors and regulation of inflammatory response at the site of inflammation; in line with this,
we detected the activation of NF-κB signaling that interconnects several inflammation regulating
pathways (Supplementary Tables S1 and S2). Based on the p-values, the most significantly activated
pathways were the “Granulocyte adhesion and diapedesis,” “Agranulocyte adhesion and diapedesis”
and “Leukocyte extravasation signaling” (Supplementary Table S1). By applying the z-score “Acute
phase response signaling,” “IL6 signaling” and “Role of pattern recognition receptors in recognition of
bacteria and viruses” pathways (Supplementary Table S2) were also highly enriched. The overview of
these circuits represents the actual status of the rat colon in the TNBS-induced colitis; thus, the sensing
of danger signals induces the expression of proinflammatory genes that, in turn, induce immune cell
infiltration into the affected tissue to restore homeostasis.
3.4. Genes Influencing Host-Microbiome Relationship during Inflammation Have Altered Expression in
IBD Patients
The relationship of the intestine and the microbiome in the lumen of the bowel is tightly regulated.
In the healthy colon, the double mucin layer precludes the direct contact of bacteria and epithelium
and protects the surface against hazardous agents [21]. The main component of this viscoelastic gel is
mucin 2 (MUC2), which arranges the firmly adherent inner layer almost without bacteria, and the outer
layer, which contains the microbiome. O-glycosylation of MUC2 serves as connection site and nutrient
source for commensal flora [22,23]. The formation of glycan chains of glycoproteins is performed by
glycosyltransferases. Glycosylation pathways are extremely complex with a contribution of several
enzymes [21]. The altered glycan profile of MUC2 was observed in active UC patients compared to
the normal glycosylation of control and inactive UC patients [24]. Arike et al. determined that the
main glycosyltransferases assist in the O-glycosylation of MUC2 in mice colon. They highlighted the
function of GalNAc-Ts, C1galt1, C1galt1c1, B3gnt6, Gcnt3 and Fut2 in the initiation step of O-glycan
formation, while in the elongation stage, B4galnt2, B3gnt3, B3gnt7, B4galt1, B3galt5 and Chst1 have
a crucial role [25]. The expression of seven out of 10 examined genes significantly decreased in the
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inflamed regions of the TNBS treated rat colons (data not shown). This may indicate the insufficient
glycosylation of mucin in the inflamed regions of rat colons.
The glycosylation in IBD does not only affect mucins, but also the formation of apical surface
of intestinal epithelial cells (IECs) and immune cell tethering [26]. In addition to the fucosylation
of MUC2 glycans, FUT2 also plays a role in the construction of glycocalyx of IECs. Together with
FUT1, FUT2 synthetize H-antigen, defining the secretor status of ABO blood group antigens [27].
FUT1 is expressed on erythrocytes, vascular endothelium; FUT2 is present on epithelial cells and in
body fluid [27]. IECs express Fut2 in response to the commensal microbiome, and the lack of Fut2 in
mice leads to higher susceptibility to intestinal inflammation against pathogens [28]. Furthermore,
genome-wide association studies demonstrate that the polymorphism of FUT2 is correlated with
CD [29]. After TNBS treatment, expression of both Fut1 and Fut2 was significantly decreased in the
inflamed regions compared to the uninflamed segments of rat colons (Supplementary Figure S3). In
the case of IBD patients the expression of FUT1 increased while the level of FUT2 mRNA decreased in
the active-inflamed colon samples (Figure 2), indicating some divergence between the course of IBD in
humans and the irritant-induced colitis in rats.
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gene expression of FUTs: FUT1, FUT2, FUT4 and NLR receptors: NOD2, NLRP3, NLRP6, NLRC4 is
shown from inactive (left), active uninflamed (middle) and active inflamed (right) colon samples of IBD
patients. Dots represent individual values, and the lines connect uninflamed and inflamed samples
from the same IBD patient; * p < 0.05.
Downregulation of FUT2 ay lead to diminished IEC fucosylation and decreased protection
against bacteria in the colon lumen, thereby promoting the progression of chronic inflammation.
3.5. Balancing between Danger and Tolerance
Perturbation of the commensal flora or the disintegration of glycosylated mucus barrier results in
the direct contact of IECs and microbiome. The innate immunity, as a first line of defense, monitors
environment l r host-derived factors and distinguishes between dangerous and safe ignals. Pattern
recognition receptors (PRR ) serve as sensors of pathogen associated molecular patterns (PAMPs) fr m
microbes in the colon lumen or damage/danger associated molecular patterns (DAMP ) derived from
dysfu ctional lls of colonic tissue. NOD-like receptors (NLRs) belong to PRRs, whose ignificant
activation w re obs rved in the TNBS tre ted r t colons (Supple entary Tables S1 and S2, Figure S2).
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Cytosolic NLRs are classified by their NATCH nucleotide-binding domains and leucine-rich
repeats, and it is also the basis of their standard nomenclature [30]. NLRs act as regulators of
antimicrobial response, colonic microbial ecology and mitochondrial antiviral immunity [31–33].
Moreover, they are the main components of the inflammasomes: a multiprotein complex that regulates
the activation of proinflammatory cytokines in a caspase-1 dependent manner [34]. It is also important
to note that the firstly identified CD susceptibility mutation affects the NLR family member NOD2,
which recognizes the bacterial cell wall component peptidoglycan and induces the expression of
proinflammatory genes [35,36]. TNBS treatment strongly influenced the expression of intracellular
NOD like receptors (Supplementary Figure S2). Three members of the NLR family had increased
expression in the inflamed colon regions (Nod2, Nlrp3, Nlrp12); in contrast, the levels of Naip5, Naip6,
Nlrc4 and Nlrp6 mRNAs decreased (Supplementary Figure S2). Inflammasome complex forming
NLRP3, NLRC4 and NLRP6 have a role in the maturation of interleukin-1 family cytokines [34,37].
NLRP3 is mostly expressed in myeloid cells, while the main sources of NLRP6 are epithelial cells of
the intestine [38]. According to a two-step model, the production and activation of NLRP3 is induced
by host and microbiota derived molecules, which results in the release of mature pro-inflammatory
interleukins [38,39]. In line with the TNBS treated rat model, expression of NLRP3 also increased in the
inflamed colon samples of IBD patients (Figure 2). In contrast, the expression of NLRP6 is regulated
by host-colonizing bacteria and its activation eventuates IL-18 maturation, which in turn controls
the production of antimicrobial peptides, hence promoting proper microbial composition [31,38]. In
addition, NLRP6 is a negative regulator of the inflammatory response and prevents DSS-induced colitis
in mice [31,40]. While in the rat model, expression of NLRP6 mRNA was slightly but not significantly
elevated in the TNBS treated uninflamed and decreased in the inflamed colon regions, it was increased
in the inflamed tissue samples from IBD patients (Figure 2, Supplementary Figure S2). The colonic
expression of NLRC4 (also known as IPAF) that recognizes bacterial flagellin and type III secretion
apparatus [41] was downregulated after TNBS treatment in the inflamed tissue areas, while in human
colonoscopy samples, the mRNA level of NLRC4 increased (Figure 2, Supplementary Figure S2). Taken
together, the expression pattern of the family of NOD-like receptors at the site of inflammation was
characterized by the increased expression of inflammation promoting NLRs and decreased expression
of NLRs with anti-inflammatory potential.
3.6. Burst of Cytokine and Chemokine Expression
Ligand binding of PRRs induces the expression of chemotactic molecules, such as cytokines and
chemokines from resident cells, resulting in the infiltration of immune cells to the damaged tissues [42].
Members of the IL-1 family, such as IL-1α, IL-1β and IL-18 have an important role in the regulation
of tissue homeostasis, inflammatory response and immune cell activation [43,44]. Although IL-1α
and IL-1β use the same IL-1R1 for binding, their expression pattern and function differ [43]. Healthy
barrier cells (such as endothelial and epithelial cells) constitutively produce considerable amounts
of IL-1α, while in hematopoietic cells, its expression is induced by pro-inflammatory stimuli [45]. In
contrast, the unique source of IL-1β are myeloid cells, where its inactive precursor must be cleaved by
the inflammasome in a caspase-1 dependent manner to gain functional form [43]. According to the
‘inflammatory loop’ model, IEC-derived IL-1α initiates inflammation and recruitment of hematopoietic
cells, which react to the inflammatory circumstances with further production of IL-1α, IL-1β and other
pro-inflammatory mediators [45]. Bersudsky et al. examined the effect of neutralizing antibodies against
IL-1α, IL-1β and IL-1 receptor in DSS-induced colitis model and observed mitigation of inflammation
after inhibition of IL-1α, whereas IL-1β blocking exacerbated the symptoms [46]. Similarly to IL-1β,
IL-18 maturation is related to inflammasomes; moreover, NLRP6 inflammasome deficiency causes
inadequate IL-18 production [44]. IL-18 plays a role in the activation of NK and Th1 cells, thereby, it is
involved in tumor control; however, the overproduction of IL-18 enhances intestinal permeability [43].
In the rat model of colitis, expression of both IL-18 and NLRP6 decreased (Supplementary Figures S2
and S5); in contrast, the expression of other members of IL-1 family were all induced, thus, the mRNA
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levels of IL-1α and IL-1β increased both in the human and rat tissues (Figure 3, Supplementary
Figures S4 and S5).
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Abnormal overexpression of pro-inflammatory TNF plays a role in the development of
inflammatory diseases, such as IBD or psoriasis. As a pleiotropic cytokine, under homeostasis, it
contributes to tissue regeneration, tumor control and defense against infections. However, uncontrolled
TNF expression triggers inflammation, activation of endothelial cells, recruitment and survival of
inflammatory cells and tissue destruction [47]. Both in the TNBS treated rat model of colitis and in
IBD patients, the xpr ssion of TNF increased in the inflamed colon samples (Figure 3, Suppleme tary
Figure S4).
TNF exerts its function through TNFRI and TNFRII (tumor necrosis factor receptor I and
II) signaling that activates NF-κB pathway, thereby regulating the transcription of both pro- and
anti-inflammatory molecules. Important negative regulators of inflammation are TNFAIP3 (TNF alpha
induced protein 3, also known as A20) and TNFAIP6 (TNF alpha induced protein 6, also known as
TSG6) [48,49]. Ubiquitin-editing enzyme TNFAIP3 is able to abolish NF-κB activation by removing
ubiquitin chains from key com onents of TNFR signaling p thway (such as RIP1 and NEMO) that leads
to their proteasomal degradation; notably, SNPs in TNFAIP3 are associated with CD [49]. TNFAIP6
belongs to the hyaluronan-binding protein family and exerts its anti-inflammatory effect by the binding
to several chemokines (e.g., CCL2, CCL7, CXCL8). As a result, the chemokines are not able to interact
with their binding partners, such as heparin or type I collagen [48]. The expression of all these negative
regulators of inflammation increased in the inflamed colon regions of rat model of colitis as well as
IBD patients, which correlates with the upregulation of their inducer TNF (Figure 3, Suppl mentary
Figure S4).
Members of the IL-6 cytokine family include IL-6, IL-11, oncostatin M (OSM), leukemia inhibitory
factor (LIF) and cardiotropin-1 (CTF1) [50,51]. IL-1β and TNF are able to induce the transcription of
IL-6 in both stromal and immune cells, thereby—under inflammatory conditions—IL-6 is a prominent
predictor of disease activity. IL-6 is a key regulator of i nate immune responses by contr lling
neutrophil accumulatio , expression of chemokines and adhesion molecules [51]. Rece tly, high OSM
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levels in IBD patients were found to be associated with failure to respond to anti-TNF therapy [52]. We
observed the significant upregulation of IL-6 and OSM signaling in the inflamed rat colons compared
to the control and to the TNBS treated uninflamed tissue samples (Supplementary Tables S1 and S2) in
line with the increased expression of IL-6 mRNA both in the TNBS induced model of colitis and in the
colon biopsies of IBD patients (Figure 3, Supplementary Figure S4).
Activation of canonical IL-10 signaling pathway was also observed in the inflamed colon of TNBS
treated rats (Supplementary Table S1). As an anti-inflammatory cytokine, IL-10 plays a role in tissue
regeneration, and IL-10 polymorphisms are also associated with IBD [53]. We measured significantly
elevated amount of IL-10 mRNA in the inflamed colons of TNBS treated rats and also in IBD patients
(Figure 3, Supplementary Figure S4).
In addition to the anti- and pro-inflammatory cytokines, chemokines are important regulators
of inflammations by influencing leukocyte recruitment [54]. These small, secreted proteins bind
to transmembrane chemokine receptors; hence, they activate intracellular pathways related to cell
movement, such as cell arrest or migration [54]. CXCL8 (also known as IL-8, functional murine
homologue of Cxcl1) exerts its effect through CXCR1 and CXCR2 receptors [55,56]. CXCL8/Cxcl1 plays
a key role in the activation and recruitment of immune cells, such as neutrophils, monocytes and
lymphocytes, while a blockade of CXCR2 or absence of Cxcl1 mitigate their infiltration to inflamed
intestine [57]. We determined that in the inflamed colon of IBD patients, the mRNA level of CXCL8
significantly increased, just as its rodent homologue Cxcl1 and its receptor, Cxcr2 in rat samples (Figure 3,
Supplementary Figures S4 and S5). CCL2 (also known as MCP-1) is responsible for the activation
of monocytes and macrophages, while CCL2 deficiency in experimental colitis reduces severity of
inflammation [58]. CXCR4 regulates the transmigration of T cells in the inflamed intestine [59]. We
observed significant upregulation of both CCL2 and CXCR4 expression in the inflamed tissues in both
rat and human samples (Figure 3, Supplementary Figure S5).
Novel therapeutic strategies are based on the suppression of pro-inflammatory cytokines
or enhancement of anti-inflammatory mediators that targets a certain molecule. Many of the
abovementioned molecules are already therapeutic targets for the reduction of IBD symptoms [60].
Currently, anti-TNF administration is the most widely used treatment against IBD symptoms. Although
anti-TNF therapy seems to be effective in many cases, activation of alternative inflammatory pathways
(e.g., IL-6 signaling) causes the development of a secondary non-response that turns anti-TNF therapy
inadequate for more than 40% of IBD patients [60]. Similarly, although the blockade of IL-6 alleviates
inflammatory symptoms, it in turn causes perforation of the intestine [60]. Interestingly, treatment
with an IL-1 receptor agonist was ineffective in clinical trials, probably due to the different functions of
its ligands [60]. IL-10, TNFAIP3 and TNFAIP6 are relatively novel targets for therapeutic applications.
Due to their immunosuppressive effect, they have a potential to alleviate inflammatory symptoms
of IBD patients. In line with this, Sala et al. successfully reduced intestinal inflammation in mice
by TNFAIP6 administration [61]. Even though the systemic application of recombinant IL-10 has
not achieved remission in IBD, the local production of IL-10 by IL-10-secreting Lactobacillus lactis is a
promising approach that is in phase I/II clinical stage [53,60].
Even though the above examples represent a great leap forward in the treatment of IBD, targeting
a certain molecule is not always fully successful. In line with this, our transcriptome analysis revealed
the complex interplay of thousands of molecules, including cytokines and chemokines that are
able to corporate, regulate or even replace each other’s function. Our genome wide transcriptome
analysis revealed that upon inflammation many molecules belonging to a given class of effectors
have synchronous alteration in their expression profile (such as upregulation of pro-inflammatory
cytokines, etc.). From this perspective, targeting common regulator/s—such as microRNAs—of
inflammation-associated molecules may have the potential to moderate the symptoms in most IBD
patients more generally.
Taken together, our data on the expression profile of cytokines and chemokines in both in vivo rat
model of experimental colitis and inflamed colon samples of IBD patients are in line with numerous
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reports [60] highlighting the key role these molecules play in promoting the evolvement of the chronic
inflammatory milieu in the bowel.
3.7. Support of Immune Cell Trafficking
Secretion of cytokines and chemokines promotes the activation of endothelial cells that, in turn,
facilitate the transmigration of leukocytes. After inflammatory stimuli, endothelial cells express
E-selectin (SELE) and p-selectin (SELP), while ligands, L-selectin (SELL) and SELPLG (also known
as p-selectin glycoprotein ligand (PSGL1)) are located on the surface of activated leukocytes [62].
Their interaction is necessary for the capture of immune cells from the blood flow [63]. We detected a
significant increase in the expression of all these molecules in the rat model of colitis (Supplementary
Figure S5) and subsequently validated their expression in inflamed colons of IBD patients, corroborating
significant induction of selectins (Figure 4).
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in the inflamed colon tissue. The relative ge e expressions of selectins SELE, SELP, SELL and their
ligand SELPLG, integrin ITGA4, ITGA5, ITGB2, ITGB7 and adhesion molecules ICAM1 and ICAM2
are shown from active (left), active uninflamed (middle) and activ infla ed (right) colon samples of
IBD patients. Dots represent individual values, an the lines connect uninflamed and inflamed samples
from the same IBD patient; * p < 0.05.
Chemoattractant-triggered leukocytes express integrin subunits (such as ITGA4, ITGA5, ITGB2,
ITGB7), which assemble into ligands of ICAM1 and VCAM1 on the surface of endothelial cells
promoting their rolling and arrest, while fibronectin (FN1) enhances this tight adherence by complex
formation with integrins [63,64]. Moesin (MSN) interconnects ICAM1 to cytoskeleton components
providing structural support during migration [62]. Similar to selectins, the expression of the above
mentioned adhesion molecules was all upregulated after TNBS treatment of rats (Supplementary
Figure S5) as well as in the inflamed colons of IBD patients (Figures 4 and 5).
Rolling of leukocytes is necessary for finding the exit site from the blood vessel that is supported by
the endothelial ligand ICAM2 [63]. Docking of circulating immune cells onto the endothelial surfaces
induce the production of matrix metalloproteinases, including MMP2, MMP12 and MMP14. MMPs
rearrange ECM and degrade junctional molecules, such as CDH5 (VE-cadherin, vascular endothelial
cadherin) or claudins to open the interendothelial way for transmigrating leukocytes [65]. MMPs also
have crucial role in the processing of cytokines and chemokines, such as TNF, IL-1β and CXCL1 [66–68].
In the inflamed rat and human colon samples, we observed a synchronous upregulation of ICAM2,
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MMP2, MMP12, MMP14 and CDH5 (Figure 5 and Supplementary Figure S5) that may promote the
diapedesis of immune cells into the involved tissue/s.
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Figure 5. Collective upregulation of matrix remodelers and adhesion molecules facilitate migration
of leukocytes through the endothelial cells of blood vessels. The relative gene expression of
extracellular matrix component FN1, ERM family member MSN, cell adhesion molecules CDH5,
matrix metalloproteinases MMP2, MMP12 and MMP14 is shown from inactive (left), active uninflamed
(middle) and active inflamed (right) colon samples of IBD patients. Dots represent individual values,
and the lines connect uninflamed and inflamed samples from the same IBD patient; * p < 0.05.
The fucosyltransferases mentioned earlier are responsible for the synthesis of CD15 (Lewis-related
carbohydrate Lex) antigens [27], in addition to controlling glycolysation of IECs and mucin glycoproteins.
FUT4 and FUT9 take a part in the formation of CD15 which is a cell surface marker of mature neutrophils,
monocytes and promyelocytes. Here, CD15 as a carbohydrate ligand of selectins, contributes to
leukocyte ad sion and diapedesis [69,70]. Cancer cells express high level of sialyl-Lex, and as a cancer
marker, elevated level of sialyl-Lex is associa ed with high chance of metastasis [71]. Through the
activation of the PI3K/Akt and NF-κB pathways, FUT4 r g ates the expression of EMT transcription
factor SNAIL and MMP9, thus promoting EMT [72]. Moreover, it is also upregulated in human
colorectal carcinomas, and the knockdown of FUT4 decreases the mesenchymal characteristic in breast
cancer cell lines [72,73]. In the TNBS-induced experimental model of colitis, we detected elevated
expression of Fut4 and Fut9 in the TNBS-treated uninflamed tissues, and decreased expression in the
inflamed regions, respectively (Supplementary Figure S3). Yet, in the human samples we have not
detected any significant alteration of FUT4 (Figure 2). Importantly, despite the reported expression of
FUT9 in human colon [74], we were unable to detect measureable amount of FUT9 transcript in the
colon samples independently of the status of inflammation, despite using three different primer and
probe sets (data not shown).
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Recruitment of immune cells is essential for the effective restoration of tissue homeostasis, which
is promoted by the increased expression of adhesion molecules. Here we have shown data on the
global activation of signaling pathways and increased expression of molecules associated with the
migration and diapedesis of immune cells in the involved colons of both rats after colitis induction
and IBD patients. Although the leukocytes may effectively eliminate the microbial agents inducing
acute inflammation, their excessive and prolonged accumulation also facilitates the establishment of
chronic inflammation. Blocking of adhesion molecules, such as integrins or their ligand ICAM1, is
a promising therapeutic approach, for instance, anti-α4β7 treatment, which represses the intestinal
homing of lymphocytes, is now used in the treatment of IBD patients [75,76].
3.8. Definition of Immune Cell Signature
Inhibition of leukocyte recruitment and infiltration to the inflamed tissue by blocking
pro-inflammatory cytokines and adhesion molecules proved to be relevant in IBD treatment. The role of
immune cells in IBD pathogenesis is indisputable, just as their dynamic fluctuation in the colon tissue.
In contrast, the scale of their exact contribution in the inflammatory process is still debated. Cellular
structure of colon tissue is characterized by resident and infiltrating cells. All of them have distinct
or overlapping functions in the maintenance of mucosal tissue homeostasis. Under pathological
conditions, such as IBD-associated intestinal inflammation, activation of innate and adaptive immune
responses triggers significant accumulation of immune cells in the involved tissues. Inflammation
subsequently induces structural reconstruction of colonic mesenchyme, for example colitis-specific
fibroblast subsets affect barrier functions and boost inflammation [77].
Sequencing of the full transcriptome of colon tissue samples from in vivo TNBS-treated rat
model of experimental colitis facilitates the monitoring of the global gene expression alteration of a
heterogeneous cell subset that is currently present at the uninflamed or in the inflamed regions (Figure 1).
Novel bioinformatics tools enable the quantitative estimation of proportion of different immune cell
types in these complex tissue samples based on transcriptomic data, by using a network–based
deconvolution approach [17]. Recently, defined markers whose collective observation determines
gene signatures of seven distinct immune cell types, termed as ImSig, have been recently released [17].
Since this application is based on data from human tissue transcriptomes, first we had to identify
the homologous Rattus norvegicus gene IDs of the Homo sapiens Immune Signature genes. Out of the
569 immune human signature genes, we have identified 476 IDs in the Complete List of Vertebrate
Homology Classes database and additional 41 homolog/orthologue IDs were identified manually
using the resources of NCBI and HGNC databases (Supplementary Tables S4 and S5). Next, we
determined the number of overlapping genes between ImSig and our transcriptomic data and applied
the recommended 75% as lower bound, while for feature selection, we used the correlation threshold at
r = 0.7 (Supplementary Table S3). As a result, we excluded the NK cells and Plasma cells categories from
further analysis, since the number of rat homologous have not reached the recommended threshold.
Based on coexpression of signature genes of ImSig approach, we observed the accumulation
of macrophages, monocytes and neutrophils primarily in the TNBS-treated inflamed colon samples,
while in the uninflamed regions their amount have not changed considerably compared to the control
samples (Figure 6). Cells of the adaptive immune response, B cells and T cells have not changed as
dramatically as macrophages, monocytes or neutrophils; furthermore, we detected higher deviation
among biological replicates. Even so, the average expression of B-cell signature genes moderately
increased in the inflamed samples; strikingly, T-cell gene signature diminished in the involved tissues
(Figure 6).
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4. Conclusions
Animal experiments are still widely used when studying various aspect of human diseases and
treatment options, with ~90% of laboratory animal experiments conducted in mice and rats. Despite
many advantages of these models, there are undoubted limitations, some arising from differences
between species others due to differences between diseases. Here, we used a rat model of TNBS-induced
experimental colitis where inflammation develops in 72 h, in contrast, IBD is a chronic disease which
often has very long duration. Even though some of the data generated on rat model could not be
validated on human samples (e.g., expression profile of FUT1, NLRP6 and NLRC4), the majority (30
out of 33) of the gene expression changes were identical, demonstrating that animal models—in this
case TNBS-induced colitis—are still useful tools in deciphering molecular mechanisms underlying
human diseases, such as IBD.
In the life of IBD patients inactive and active disease phases fluctuate, while the localization of
inflamed and uninflamed colon regions alternates along the digestive tract. This course is coupled with
the fluctuation of the expression of genes regulating inflammation. Here, we report a genome-wide
alteration in the expression pattern of inflammation-related gene sets in the TNBS-treated rat model
of colitis, and the validation of a subset of these genes on samples derived from IBD patients. As a
barrier tissue, the intestinal epithelium is constantly exposed to the colonizing bacteria from the lumen;
in line with the perturbation of commensal gut bacteria, termed as dysbiosis, that is characteristic
in IBD patients. Here, we measured the expression pattern of genes related to glycosylation and
recognition of PAMPs/DAMPs. Absence of fucoslytransferases (FUT2) may affect the protection of
colonic epithelium, while damaged cell-derived alarmins activate various immune cells through
pattern recognition receptors, such as NLRs. Induction of inflammatory cytokines and chemokines
leads to the recruitment and homing of leukocytes.
Colon tissue is composed of several cell types, and all of them contribute differently to the
maintenance of mucosal homeostasis or to the regulation of immune response. In the present
work, we monitored the actual gene expression alteration of a heterogenic cell population present
in the uninflamed or inflamed regions of rat and human tissue samples. The rapid development
of single-cell sequencing methods allows for increased resolution of our transcriptome analysis by
applying single-cell RNA-Seq (scRNA-Seq) and determine the gene expression alteration of specific
cell types in the inflamed vs. uninflamed colon tissues.
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